Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

The funding is set to support various activities, including the launch of a confirmatory study of bitopertin for ...

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

Secondary Myelofibrosis Therapeutics MarketThe global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that, following feedback from the U.S. Food and Drug ...